How I'm using £120 a month to aim for £12500 a year in passive income! – Motley Fool UK

Everyone wants to earn passive income, right? Well I’m looking to invest the money I don’t need now, to generate £12,500 a year for my retirement.
Image source: Getty Images
Dividend stocks providing me with passive income form a considerable part of my portfolio. However, I’m fortunate in that I don’t need this passive income right now. Instead, I reinvest my dividend payments to generate wealth in the long run.
This allows me to benefit from something called compound interest. This is essentially the process of earning interest on my interest. And the longer I leave it, the more I earn.
So, let’s take a look at how I could turn £120 a month into £12,500 a year.
Compounding returns does not guarantee success, but I contend that it carries less risk than investing in growth stocks.
I’m actually still a fairly long way from retirement, so I’m going to be investing for the next 40 years.
If I were to start with £10,000 and put away £120 every month for the next 40 years, and invest and reinvest in dividend stocks with 5% yields, at the end of four decades, I’d have a whopping £250,000.
And with £250,000 invested in stocks paying a 5% yield, I can expect to earn an impressive £12,500 a year in dividend payments. That’s a pretty handy return given I would have been investing less than £1,500 a year.
But the longer I leave it, the more money I’ll have. Having said that, I’ll be getting fairly old in 40 years, so maybe it’s best I don’t leave it too long!
It’s also worth noting that the more money I put in now, the more I’ll have in the future. It sounds obvious but compound interest has the capacity to make my investments multiply.
Investing for the long run can be tricky, after all none of us know exactly what the market is going to look like in 20, 30, or 40 years’ time.
However, there are a few things that I’m fairly sure of. The first is that tobacco companies aren’t going to be selling tobacco anymore, at least not in the UK, and that means these firms will have to complete their transition towards smoking alternatives. This might not be so profitable.
I’m also concerned about investing in things like fast food stocks. I see there being increasing need to encourage healthy lifestyles, particularly in the West, where we have a growing ageing population.
Dividend yields change as payments vary and share prices go up and down, but I’m looking at solid UK value stocks, such as Lloyds, HSBC and Barratt Developments.
These three stocks provide decent yields, averaging around 5%. I’m also confident that banks and housing developers are still going to be operating in the years to come.
I’d also look at healthcare giants such as GSK, which is down right now due to lawsuits in the US. However, it’s unlikely that this issue will put GSK out of business.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.
James Fox owns shares in Lloyds, GSK, HSBC and Barrett Developments. The Motley Fool UK has recommended GSK plc, HSBC Holdings, and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
| Alan Oscroft
I’m always on the lookout for my next share to buy. But I’d taken my eye off this one after…
Read more »
| Dr. James Fox
The FTSE 100 may have closed above 7,500 earlier this week, but many stocks still haven’t recovered. So, here are…
Read more »
| Christopher Ruane
As inflation rises, our writer is trying to earn passive income by owning dividend shares. Here are two he’s bought…
Read more »
| Alan Oscroft
How can Warren Buffett’s guidance help us to pick the most profitable companies to invest in over the next couple…
Read more »
| Dr. James Fox
Scottish Mortgage shares came crashing down last year after a multi-year bull run. But would I have made money if…
Read more »
| Edward Sheldon, CFA
Legal & General has paid out some monster dividends in recent years. Here, Edward Sheldon looks at the dividend forecast…
Read more »
| Charlie Keough
Rolls-Royce shares have faced numerous setbacks in the recent past. However, could now be the time to buy? This Fool…
Read more »
| Edward Sheldon, CFA
Shares in both GSK and its spin-off Haleon have plummeted this week. Edward Sheldon looks at what’s going on and…
Read more »
View All
Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.
To make the world Smarter, Happier, And Richer
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show and premium investing services.
Read more about us >

We have taken reasonable steps to ensure that any information provided by The Motley Fool Ltd, is accurate at the time of publishing. Any opinions expressed are the opinions of the authors only. The content provided has not taken into account the particular circumstances of any specific individual or group of individuals and does not constitute personal advice or a personal recommendation. No content should be relied upon as constituting personal advice or a personal recommendation, when making your decisions. If you require any personal advice or recommendations, please speak to an independent qualified financial adviser. No liability is accepted by the author, The Motley Fool Ltd or Richdale Brokers and Financial Services Ltd for any loss or detriment experienced by any individual from any decision, whether consequent to, or in any way related to the content provided by The Motley Fool Ltd; the provision of which is an unregulated activity.
The value of stocks, shares and any dividend income may fall as well as rise and is not guaranteed, so you may get back less than you invested. You should not invest any money you cannot afford to lose, and you should not rely on any dividend income to meet your living expenses. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, administrative costs, withholding taxes and different accounting and reporting standards. They may have other tax implications, and may not provide the same, or any, regulatory protection. Exchange rate charges may adversely affect the value of shares in sterling terms, and you could lose money in sterling even if the stock price rises in the currency of origin. Any performance statistics that do not adjust for exchange rate changes are likely to result in an inaccurate portrayal of real returns for sterling-based investors.
Fool and The Motley Fool are trading names of The Motley Fool Ltd. The Motley Fool Ltd is an appointed representative of Richdale Brokers & Financial Services Ltd who are authorised and regulated by the Financial Conduct Authority (FRN: 422737). In this capacity we are permitted to act as a credit-broker, not a lender, for consumer credit products. We may also publish information, opinion and commentary about consumer credit products, loans, mortgages, insurance, savings and investment products and services, including those of our affiliate partners. We do not provide personal advice and we will not arrange any products on your behalf. Should you require personal advice, you should speak to an independent, qualified financial adviser.
The Motley Fool Ltd. Registered Office: 5 New Street Square, London EC4A 3TW. | Registered in England & Wales. Company No: 3736872. VAT Number: 188035783.
© 1998 – 2022 The Motley Fool. All rights reserved. The Motley Fool, Fool, and the Fool logo are registered trademarks of The Motley Fool Holdings Inc.


Leave a Comment